Welcome : Guest

MOLECULAR DIAGNOSTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousand by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as -

Abbott Laboratories
Abbott Molecular, Inc.
Becton, Dickinson and Company
bioMérieux SA
Cepheid

Click here to request a full list of companies covered in the report...

Code: MCP-1226
Price: $4950
Companies: 145
Pages: 601
Date: August 2016
Market Data Tables: 123
  Status: * New Report



TABLE OF CONTENTS


  MOLECULAR DIAGNOSTICS (Complete Report) Pages : 601   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Global In-Vitro Diagnostics (IVD) Market on a Steady Growth Path.....II-1 1$100
   Table 1: Global In-Vitro Diagnostics Market by Segment (2015): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Hemostasis (includes corresponding Graph/Chart).....II-2

Table 2: Global In-Vitro Diagnostics Market by Geographic Region (2015): Percentage Breakdown of Value Sales for the United States, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart).....II-2
Molecular Diagnostics – A Rapidly Expanding Segment of the IVD Market.....II-2
2$350
   PCR Technology Leads the MDx Market.....II-41$100
   Current and Future Analysis.....II-5
US and Europe – Leaders in Molecular Diagnostics Adoption.....II-5
1$100
   Developing Countries Excel in Growth Prospects.....II-61$100
   Major Growth Drivers.....II-71$100
   Key Market Trends in a Nutshell.....II-8
Major Technology Trends.....II-8
Advancements in Molecular Diagnostics – A Boon for the Industry.....II-8
1$100
   Major Issues and Challenges.....II-9
Market Outlook.....II-9
4$400
   Aging Population Drives Molecular Diagnostics Market.....II-13
Global Aging Population Statistics – Opportunity Indicators.....II-13
Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart).....II-13
1$350
   Table 4: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart).....II-141$350
   Table 5: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart).....II-15
Technological Innovations Set to Drive the Market.....II-15
1$350
   The Role of Molecular Diagnostics in Personalized Medicine.....II-161$100
   Companion Diagnostics Make Way for Personalized Medicine.....II-171$100
   List of Select FDA-Cleared Companion Diagnostic Devices.....II-181$100
   Biomarkers as Companion Diagnostics.....II-19
Rise in Healthcare Spending in Developing Nations Bode Well for Market Growth.....II-19
1$100
   Table 6: Select Countries with Healthcare Spending as a Percentage of GDP (2014) (includes corresponding Graph/Chart).....II-20
Proteomics Technologies: Growing in Significance.....II-20
1$350
   New Developments in Proteomics Technologies.....II-211$100
   New Applications Hold Promising Potential.....II-221$100
   Molecular Diagnostics for Lymphoid Malignancies.....II-23
Next-Generation Sequencing Technologies Keep Up the Momentum.....II-23
1$100
   Select Commercial NGS Technologies.....II-24
Rising Emphasis on Lab Automation to Augur Well for Market Growth.....II-24
2$200
   List of Fully Automated and Rapid Molecular Diagnostics.....II-26
Molecular Diagnostics and Intellectual Property.....II-26
Molecular Diagnostics – Moving from Centralization to Decentralization.....II-26
1$100
   Limited Reimbursements by Third Party Payers – A Stumbling Block.....II-271$100
   Infectious Diseases.....II-28
Table 7: World Molecular Diagnostics Market for Infectious Diseases by Test Type: Percentage Share Breakdown for the Year 2015 (includes corresponding Graph/Chart).....II-28
1$350
   Bright Prospects Ahead for Molecular Diagnostics for Testing Infectious
  Diseases.....II-29
1$100
   Leading Players.....II-30
Key Trends.....II-30
Increasing Incidence of Infectious Diseases Fuels Adoption.....II-30
1$100
   Table 8: Reported Cases of Major Infections by Select Geographic Region: 2011.....II-311$350
   Rising Incidence of Hospital Acquired Infections Propels Market Growth.....II-32 1$100
   Table 9: Comparison of Different Parameters for Select C. diff MDx Tests.....II-33
Rising HIV Prevalence Provides Ample Growth Opportunities.....II-33
1$350
   Table 10: HIV Infection Statistics Worldwide: As of 2014 (includes corresponding Graph/Chart).....II-34

Table 11: Worldwide HIV Prevalence and Incidence (in Million) by Region: 2014 (includes corresponding Graph/Chart).....II-34
1$350
   Table 12: Worldwide AIDS Related Deaths by Geographic Region: 2014 (includes corresponding Graph/Chart).....II-35

Table 13: HIV Prevalence (%) in Adults (15-49 years) by Year: Prevalence Percentage in Adults in 1990, 2000, 2008 & 2014 (includes corresponding Graph/Chart).....II-35
1$350
   Infectious Disease Testing – A Major Driver of Molecular Diagnostics Market.....II-361$100
   Select FDA-Cleared Molecular Diagnostic Tests for Infectious Diseases.....II-373$300
   Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market.....II-401$100
   Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing.....II-411$100
   HPV Testing: A Fast Growing Segment in the Molecular Diagnostic Testing
  Market.....II-42
1$100
   List of Select HPV Molecular Diagnostic Tests by Company and Technique.....II-43
Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing.....II-43
2$200
   Major Risk Factors to HPV/Cervical Cancer.....II-45
Table 14: Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Graph/Chart).....II-45
1$350
   Table 15: World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Graph/Chart).....II-46

Table 16: Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in ‘000s) (includes corresponding Graph/Chart).....II-46
1$350
   HPV Testing for Primary Screening Indication Bodes Well for the Market’s
  Growth.....II-47
1$100
   Archaic TB Diagnostic Methods Opens Up Opportunities for Molecular
  Diagnostics.....II-48
1$100
   List of Select Commercially-Available TB Diagnostics.....II-49
An Overview of Select TB Diagnostics under Development.....II-49
Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential
  .....II-49
1$100
   PCR Plays a Vital Role in the Diagnosis of Infectious Diseases.....II-501$100
   Blood Screening.....II-51
Molecular based Tests Ingrain Roots in Blood Donor Screening Segment.....II-51
1$100
   Cancer Screening & Diagnosis.....II-52
Overview.....II-52
1$100
   Molecular Tests Lead the Way for Cancer IVD Market Growth.....II-53
Molecular Markers to Enhance Thyroid Cancer Diagnosis.....II-53
1$100
   Oncology-Based Molecular Diagnostics: The Propitious Segment.....II-542$200
   List of US-FDA Approved Biomarkers for Cancer.....II-56 1$100
   Table 17: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart).....II-571$350
   Table 18: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart).....II-581$350
   Table 19: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart).....II-59
Growing Popularity of Chemo-Sensitivity Testing of CTCs.....II-59
1$350
   Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers.....II-60
Other Testing Applications.....II-60
Genetic Disease Testing Applications.....II-60
Overview.....II-60
1$100
   Pharmacogenomics – Prognosis Based on Genomics.....II-611$100
   Pharmacogenomics Development Augurs Growth of Genetic Testing Market.....II-62
Prospects for Genetic Diagnostics and Testing Grow Brighter.....II-62
2$200
   List of Select FDA-Cleared Genetic Tests by Disease.....II-64
Genetic Testing – An Indispensible Tool for Cystic Fibrosis.....II-64
1$100
   Table 20: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart).....II-651$350
   Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions.....II-66
Non-Invasive Prenatal Diagnostics – The Way Ahead.....II-66
Nucleic Acid Amplification Methods for Detection of Antimicrobial
  Resistance.....II-66
1$100
   PCR-Based Nucleic Acid Amplification for Detection of Antimicrobial Agents.....II-67
Histocompatibility Testing.....II-67
Table 21: Global HLA Testing Market: Revenue Estimates for 2012 through 2016 (in US$ Million) (includes corresponding Graph/Chart).....II-67
1$350
   An Overview of Competitive Landscape in Molecular Diagnostics.....II-68
Table 22: Global Molecular Diagnostics Market by Leading Player (2015): Percentage Share Breakdown by Value Sales for Roche, Qiagen, Abbott, GenProbe, Siemens, and Others (includes corresponding Graph/Chart).....II-68
1$350
   Other Noteworthy Companies and their Competitive Position by Segment.....II-69
Key Players and Their Technologies.....II-69
The Top Tier.....II-69
1$100
   Mid-Sized and Small Companies.....II-70
Cepheid: Unquestioned Leader in the Rapid and Automated MDx Market.....II-70
1$100
   Table 23: Price Comparison of Select Fully Automated and Rapid Molecular Diagnostics.....II-71
Qiagen: The Leading Player in the Global HPV MDx Market.....II-71
1$350
   Comparative Analysis of Select HPV MDx Tests.....II-72
Competitive Dynamics in the C. difficile Testing Market.....II-72
Table 24: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2015): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian, and Others (includes corresponding Graph/Chart).....II-72
1$350
   List of Select Molecular C. difficile Test Products.....II-73
Competition in the Blood Screening MDx Market.....II-73
Table 25: Global Blood Screening MDx Market by Leading Players (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Roche, and Others (includes corresponding Graph/Chart).....II-73
Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market.....II-73
1$350
   Competitive Landscape in the Global RT-PCR Market.....II-74
Table 26: Leading Players in Global RT-PCR Instruments Market (2012): Percentage Breakdown of Value Sales for Life Sciences Research by Leading Players - Thermo Fischer, Bio-Rad, Roche, Agilent, Qiagen and Others (includes corresponding Graph/Chart).....II-74
1$350
   Select Real-Time PCR Products by Company.....II-75
Competition Heats Up in dPCR Market.....II-75
1$100
   Table 27: Leading dPCR Systems At a Glance.....II-76
Life Sciences Companies Eye on Lucrative Prostate Cancer MDx Market.....II-76
1$350
   Consolidation Activity Continues to Strengthen Driven by New Entrants.....II-771$100
   Major M&A Transactions in Molecular Diagnostics: 2011-2016.....II-781$100
   Product Marketing – Key to Commercial Success.....II-791$100
   Molecular Diagnostics – Definition & Scope.....II-80
Molecular Diagnostics – Impact on Healthcare.....II-80
1$100
   Utility of Molecular Diagnostic Tests.....II-81
Background of Molecular Diagnostics.....II-81
1$100
   Major Milestones in the Evolution of Molecular Diagnostics.....II-821$100
   Types of Molecular Diagnostics.....II-83
Conventional Diagnostics Vs. Molecular Diagnostics.....II-83
Unabated Developments in Molecular Diagnostics Technology.....II-83
1$100
   Signal Amplification Technologies.....II-84
PCR – New Developments.....II-84
1$100
   Quantitative Real-Time PCR for Molecular Diagnostics.....II-85
Signal Detection and Quantification.....II-85
Quantitative Real-Time RT-PCR Analysis.....II-85
Applications of Quantitative Real-Time PCR Analysis.....II-85
1$100
   Digital PCR.....II-86
Non-PCR Methods.....II-86
Other Signal Amplification Technologies.....II-86
1$100
   DNA Probe Based Products.....II-87
Direct Detection of Specific Nucleic Acid Sequences.....II-87
Nucleic Acid Amplification and Detection.....II-87
1$100
   DNA Sequencing and Gene Detection.....II-88
Arrays of Immobilized Probes (DNA Chips) in Gene Detection.....II-88
RNA Diagnostics.....II-88
1$100
   Complementary Molecular Diagnostic Technologies.....II-89
Fluorescent In-Situ Hybridization (FISH).....II-89
DNA Biochips/Microarrays.....II-89
1$100
   Biosensors.....II-90
Proteomic Technologies for Molecular Diagnostics.....II-90
1$100
   Nanotechnology for Molecular Diagnostics.....II-91
Technologies on the Anvil.....II-91
Haplotype Analysis – A Distant Possibility.....II-91
1$100
   Chronic Multi-Gene Defects Now Diagnosable.....II-92
Whole Genome Sequencing – A Boon or a Bane to Genetic Testing?.....II-92
1$100
   Qiagen Introduces New Diagnostic Test for Cervical Cancer.....II-93
GE Showcases Discovery MI and Discovery NM/CT 670 CZT.....II-93
Quest Launches New Tests for Determining Hereditary Cancer.....II-93
Predictive Launches Test for Spine Deformities.....II-93
LabCorp® Introduces Epi proColon®.....II-93
Agena Rolls Out MassARRAY® Dx.....II-93
Rosetta Introduces Three New Diagnostic Offerings.....II-93
1$100
   bioMérieux Rolls Out GENE-UP®.....II-94
Roche Introduces New cobas Range.....II-94
Quest Launches Dako's PD-L1 Complementary Diagnostic Test.....II-94
Quest Introduces Dako’s PD-L1 Tests for KEYTRUDA®.....II-94
Clarient Rolls Out PD-L1 Test for KEYTRUDA®.....II-94
Pathway Unveils CancerIntercept™.....II-94
Cepheid Unveils Xpert® Carba-R update.....II-94
Cepheid Launches GeneXpert® Omni.....II-94
1$100
   AlphaImpactRx Introduces BrandImpactDx.....II-95
BioNTech AG Introduces MammaTyper®.....II-95
EKF Showcases Molecular Diagnostics Products Series.....II-95
Microbix Unveils New Molecular Diagnostics Range.....II-95
Roche Introduces cobas® Liat System.....II-95
Quest Unveils BRCAvantage Plus.....II-95
Cepheid Rolls Out Xpert® TV.....II-95
OpGen Introduces Acuitas™ MDRO Gene Test.....II-95
1$100
   DaVita Introduces Molecular Diagnostic Testing.....II-96
Grifols Obtains CE-Marking for ID CORE XT Molecular Diagnostic Kit.....II-96
QIAGEN Rolls Out careHPV™ Test in India.....II-96
QIAGEN Gets PMA Approval from the US FDA for artus® CMV RGQ MDx Kit.....II-96
Alere Obtains FDA Approval for Alere™ i Influenza A and B Test.....II-96
Qiagen Obtains Approval from the US Health Regulators for Gene-Testing Kit.....II-96
1$100
   Immucor Obtains the US FDA Approval for PreciseType HEA Test.....II-97
Biocartis Introduces Idylla™.....II-97
Roche Introduces cobas 6800/8800 Systems.....II-97
Roche Unveils CINtec PLUS*.....II-97
Roche Rolls Out cobas® HIV-1 and cobas HCV assays.....II-97
1$100
   Bio-Techne to Acquire Advanced Cell Diagnostics.....II-98
Myriad Acquires Sividon Diagnostics.....II-98
Siemens Acquires Neo New Oncology.....II-98
Luminex to Acquire Nanosphere.....II-98
DiaSorin Completes Acquisition of Focus Diagnostics.....II-98
Avant Acquires Amarantus Diagnostics.....II-98
HTG to Collaborate With Bristol-Myers Squibb.....II-98
1$100
   Miroculus to Acquire Kapplex.....II-99
Cepheid’s Xpert® MRSA NxG Gets European Approval.....II-99
SpeeDx Collaborates with Goffin Molecular.....II-99
FDA Approves BD’s Totalys™.....II-99
CE Mark Approves BioFire Diagnostics’ FilmArray®.....II-99
Thermo Fisher Acquires Affymetrix.....II-99
Qiagen Collaborates with Mirati.....II-99
BioGenex to Commence Operations from India Center.....II-99
1$100
   Illumina Collaborates with investors to Launch GRAIL.....II-100
Thermo Fisher Collaborates with Karolinska Institute.....II-100
CE Mark Approves Aptima® HCV Quant Dx Assay by Hologic.....II-100
FDA Approves BioFire Diagnostics’ FilmArray®.....II-100
ERBA Acquires Lumora.....II-100
Seegene Collaborates with BD Life Sciences.....II-100
MDxHealth to Acquire NovioGendix.....II-100
Quest’s Simplexa HSV 1 & 2 Test Gets FDA 510(k) Approval.....II-100
1$100
   Burning Rock Partners with Illumina.....II-101
GE’s Low Dose CT Screening Approved by FDA.....II-101
Roche to Acquire GeneWEAVE BioSciences.....II-101
Cancer Genetics Acquires Response Genetics, Inc.....II-101
OpGen Acquires AdvanDx.....II-101
Hitachi Collaborates with QIAGEN.....II-101
OPKO Takes Over Bio-Reference Laboratories.....II-101
Sysmex Signs Agreement with IndivuTest.....II-101
1$100
   CE Mark Approves Xpert® HIV-1 Qual by Cepheid and FIND.....II-102
Xpert® HCV Viral Load by Cepheid gets CE Mark Approval.....II-102
Rosetta Acquires CynoGen.....II-102
Microbix Signs Agreement with Microbiologics.....II-102
Cepheid Receives Emergency Use Authorization by FDA for Ebola Test.....II-102
Novigenix Acquires Colox®.....II-102
Roche Takes Over Signature Diagnostics.....II-102
CE Mark Approves QIAGEN’s Circulating Tumor DNA Test.....II-102
1$100
   Amarantus Completes Acquisition of DioGenix.....II-103
Aegis Acquires Diagnovus.....II-103
Empire Announces Acquisition of ID Labs.....II-103
OncoGxSelect™ Receives NJDH Approval.....II-103
Roche Takes Over Ariosa.....II-103
FDA Approves Xpert® Norovirus by Cepheid.....II-103
Cepheid’s Xpert® Flu/RSV XC Gets FDA Approval.....II-103
Roche’s cobas® Strep A Test Receives 510(k) Clearance.....II-103
1$100
   PDI Takes Over RedPath.....II-104
Veracyte Acquires Allegro Diagnostics.....II-104
GTCR Takes Over XIFIN.....II-104
QIAGEN to Collaborate with AstraZeneca.....II-104
BD Collaborates with MD Anderson Cancer Center.....II-104
Roche Acquires IQuum.....II-104
Myriad to Acquire Crescendo Bioscience.....II-104
Co-Diagnostics Unveils Co-Dx™.....II-104
1$100
   bioMérieux Acquires BioFire Diagnostics.....II-105
Thermo Fisher Scientific Acquires Life Technologies.....II-105
Myriad Genetics Takes Over Crescendo Bioscience.....II-105
AUT University Collaborates with Roche Diagnostics.....II-105
Corgenix Medical Obtains NIH Grant to Advance Development of Ebola Rapid Diagnostic
  Test Kit.....II-105
Cepheid Collaborates with AstraZeneca, Cubist Pharmaceuticals and GSK.....II-105
1$100
   B Braun US and CeGaT Join Forces to Establish B Braun CeGaT.....II-106
Provista Diagnostics Expands Exclusive License Agreement for Certain Biomarker and
  Autoantibody Technologies.....II-106
Veracyte and Fleury Partner to Offer the Afirma® Gene Expression Classifier.....II-106
Integrated Diagnostics Attracts Financing for Xpresys Lung Molecular Diagnostic Blood
  Test.....II-106
MDxHealth Enters into Agreement with Galaxy Health.....II-106
QIAGEN Acquires Exclusive Worldwide License to CALR Biomarker.....II-106
1$100
   Zyomyx Obtains $7.5 Million from UNITAID to Launch MyT4™ POC CD4 Test.....II-107
Human Longevity Inc. Commences its Operations.....II-107
Roche Takes Over IQuum.....II-107
Myriad Genetics and Sividon Diagnostics Ink Exclusive Co-Marketing Agreement.....II-107
1$100
   Abbott Laboratories (US).....II-108
Abbott Molecular, Inc. (US).....II-108
1$100
   Becton, Dickinson and Company (US).....II-109
bioMérieux SA (France).....II-109
1$100
   Cepheid (US).....II-1101$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-111
RMD’s Product Portfolio by Segment.....II-111
1$100
   RMD’s Major Test Offerings by Application.....II-112
GE Healthcare (US).....II-112
1$100
   Grifols International, S.A. (Spain).....II-1131$100
   Hologic, Inc. (US).....II-1141$100
   QIAGEN N.V. (The Netherlands).....II-1151$100
   Quest Diagnostics, Inc. (US).....II-1161$100
   Siemens Healthcare GmBH (Germany).....II-117
Tecan Group Ltd. (Switzerland).....II-117
1$100
   The ELITechGroup SAS (France).....II-118
Thermo Fisher Scientific (US).....II-118
2$200
   Table 28: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1201$350
   Table 29: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1211$350
   Table 30: World 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-1221$350
   Molecular Diagnostics Market by Application.....II-123
Table 31: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-123
1$350
   Table 32: World Historic Review for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1241$350
   Table 33: World 14-Year Perspective for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-1251$350
   Table 34: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1261$350
   Table 35: World Historic Review for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1271$350
   Table 36: World 14-Year Perspective for Molecular Diagnostics in Blood Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-1281$350
   Table 37: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1291$350
   Table 38: World Historic Review for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1301$350
   Table 39: World 14-Year Perspective for Molecular Diagnostics in Cancer Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-1311$350
   Table 40: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1321$350
   Table 41: World Historic Review for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1331$350
   Table 42: World 14-Year Perspective for Molecular Diagnostics in Other Applications by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-1341$350
   A. Market Analysis.....III-1
US Molecular Diagnostics Market Maintain its Growth Momentum.....III-1
1$75
   Competitive Landscape.....III-21$75
   qPCR and dPCR Instrumentation in the US: An Overview.....III-3
Ageing Demographics: Major Driving Factor.....III-3
1$75
   Table 43: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-4
Increasing Incidence of Chronic Diseases Drives Focus onto Molecular
  Diagnostics.....III-4
1$200
   US Individualized Medicine Market to Witness Significant Growth.....III-5
Companion Diagnostics Market in the US.....III-5
1$75
   List of Select FDA-Cleared Companion Diagnostics.....III-61$75
   Burgeoning Potential for Genetic Testing.....III-71$75
   Direct-to-Consumer Testing – A Growing Market.....III-8
Epidemic Proportion of Cancer in the US – Key Driver for Cancer Genetic
  Testing.....III-8
1$75
   Table 44: New Cancer Cases in the US by Gender and Affected Site: 2014 (includes corresponding Graph/Chart).....III-91$200
   Table 45: Incidence of Cancer for All Body Sites by Gender & Age Group in the US (2013): New Cancer Cases for Males & Females for the Age Groups Under 45 years; 45 years and Above; Under 65 years; 65 years and Above (includes corresponding Graph/Chart).....III-10
Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing.....III-10
1$200
   List of FDA-Cleared CF MDx Tests.....III-11
Molecular Diagnostics Tests Gaining Share in STD Testing Domain.....III-11
HPV Testing Market – A Review.....III-11
1$75
   Table 46: Prevalence of HPV in the US by Age (includes corresponding Graph/Chart).....III-12

Table 47: Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Graph/Chart).....III-12
1$200
   Table 48: Number of New Cervical Cancer Cases by US State (2015).....III-131$200
   Competitive Landscape.....III-14 1$200
   Table 49: Leading Players in the US HPV Testing Market (2013): Percentage Share Breakdown of Revenues for Hologic, QIAGEN, and Others (includes corresponding Graph/Chart).....III-15
List of FDA Approved HPV MDx Tests.....III-15
Regulatory Environment.....III-15
1$200
   FDA Regulations.....III-16
Clinical Laboratory Improvement Amendments (CLIA).....III-16
2$150
   Table 50: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Laboratories by Certificate Type (includes corresponding Graph/Chart).....III-18

Table 51: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Labs by Lab Type (includes corresponding Graph/Chart).....III-18
1$200
   Genetic Testing.....III-19
FDA to Implement Strict Measures for Cervical Cancer Screening Tests.....III-19
1$75
   Limited Reimbursements – A Major Hindrance.....III-20
New MoPath Codes for Reimbursement for Molecular Diagnostics Tests.....III-20
1$75
   Product Launches/Approvals.....III-213$225
   Strategic Corporate Developments.....III-246$450
   Select Key Players.....III-307$525
   B. Market Analytics.....III-37
Table 52: The US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-37
1$200
   Table 53: The US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-381$200
   Table 54: The US 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
Current and Future Analysis.....III-40
1$75
   Cancer Incidence in Canada: Opportunity Indicator.....III-41
Table 55: New Cancer Cases in Canada by Gender and Affected Site: 2014 (includes corresponding Graph/Chart).....III-41
1$200
   Table 56: New Cancer Cases in Canada by Province: 2014 (includes corresponding Graph/Chart).....III-421$200
   Table 57: New Cancer Cases in Canada by Age Group: 2014 (includes corresponding Graph/Chart).....III-43
Product Approval.....III-43
1$200
   Strategic Corporate Development.....III-44
B. Market Analytics.....III-44
Table 58: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-44
1$200
   Table 59: Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-451$200
   Table 60: Canadian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-461$200
   A. Market Analysis.....III-47
Current and Future Analysis.....III-47
Demographics Drive Market Growth.....III-47
Table 61: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart).....III-47
1$200
   Strategic Corporate Development.....III-48
B. Market Analytics.....III-48
Table 62: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-48
1$200
   Table 63: Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-491$200
   Table 64: Japanese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-501$200
   A. Market Analysis.....III-51
Current and Future Analysis.....III-51
1$75
   Insight into Molecular Diagnostics Markets in Europe.....III-52
Table 65: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart).....III-52
1$200
   Increasing Testing Needs of the Elderly: Business Case for Molecular
  Diagnostics.....III-53
Table 66: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart).....III-53
1$200
   PCR Reagents in Europe: An Overview.....III-54
Automated Systems Gain Preeminence.....III-54
Oncology-based Molecular Diagnostics Holds Immense Potential.....III-54
1$75
   Table 67: Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart).....III-551$200
   European Personalized Medicine Market to Exhibit Robust Growth.....III-56
HPV Testing in Europe: An Overview.....III-56
Table 68: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart).....III-56
1$200
   Table 69: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart).....III-57

Table 70: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart).....III-57
1$200
   Table 71: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart).....III-58
List of Select CE-Marked HPV Molecular Diagnostic Tests.....III-58
1$200
   Cervical Cancer Screening in Europe – A Review.....III-59 1$75
   Table 72: Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Graph/Chart).....III-601$200
   Table 73: Cervical Cancer Incidence and Mortality in European Countries (2012).....III-611$200
   Table 74: Prevalence of Cervical Cancer in European Countries (2012).....III-621$200
   Table 75: European HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart).....III-63
Strategic Corporate Developments.....III-63
1$200
   B. Market Analytics.....III-64
Table 76: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-64
1$200
   Table 77: European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-651$200
   Table 78: European 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-661$200
   Table 79: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-671$200
   Table 80: European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-681$200
   Table 81: European 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-691$200
   A. Market Analysis.....III-70
Current and Future Analysis.....III-70
Product Launch.....III-70
Strategic Corporate Developments.....III-70
1$75
   Select Key Players.....III-712$150
   B. Market Analytics.....III-73
Table 82: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-73
1$200
   Table 83: French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-741$200
   Table 84: French 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-751$200
   A. Market Analysis.....III-76
Current and Future Analysis.....III-76
Product Launches.....III-76
1$75
   Strategic Corporate Developments.....III-77
Siemens AG – A Key Player.....III-77
2$150
   B. Market Analytics.....III-79
Table 85: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-79
1$200
   Table 86: German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-801$200
   Table 87: German 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-811$200
   A. Market Analysis.....III-82
Current and Future Analysis.....III-82
Strategic Corporate Development.....III-82
1$75
   B. Market Analytics.....III-83
Table 88: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-83
1$200
   Table 89: Italian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-841$200
   Table 90: Italian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-851$200
   A. Market Analysis.....III-86
Current and Future Analysis.....III-86
SMIP for Pharmacogenomic Testing.....III-86
1$75
   B. Market Analytics.....III-87
Table 91: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-87
1$200
   Table 92: The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-881$200
   Table 93: The UK 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-891$200
   A. Market Analysis.....III-90
Current and Future Analysis.....III-90
Spain – Poised to become a Reckoning Force in Personalized Medicines.....III-90
Strategic Corporate Development.....III-90
1$75
   Grifols International, S.A. – A Key Player.....III-911$75
   B. Market Analytics.....III-92
Table 94: Spanish Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-92
1$200
   Table 95: Spanish Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-931$200
   Table 96: Spanish 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-941$200
   Market Analysis.....III-95
Table 97: Russian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-95
1$200
   Table 98: Russian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-961$200
   Table 99: Russian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-971$200
   A. Market Analysis.....III-98
Current and Future Analysis.....III-98
Product Launches/Approvals.....III-98
1$75
   Strategic Corporate Developments.....III-991$75
   Key Players.....III-1003$225
   B. Market Analytics.....III-103
Table 100: Rest of European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-103
1$200
   Table 101: Rest of European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1041$200
   Table 102: Rest of European 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-1051$200
   A. Market Analysis.....III-106
Current and Future Analysis.....III-106
Healthcare Spending in Asia-Pacific: On the Rise.....III-106
In-vitro Diagnostics Market: India & China Offer Significant Growth
  Opportunities.....III-106
1$75
   Table 103: China and India Leads Global Population (July 2013): Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Million) by Age Group (includes corresponding Graph/Chart).....III-1071$200
   Table 104: Age-wise Breakup of China and India’s Population Vis-à-vis Other Populous Countries Globally: As of July 2013 (includes corresponding Graph/Chart).....III-108
Molecular Diagnostics Testing Opens New World of Possibilities.....III-108
1$200
   Recent Advancements in Molecular Diagnostics Market: A Quick Review.....III-109
Novel Genetic Testing Methods.....III-109
Development of Personalized Healthcare Approaches.....III-109
1$75
   Molecular Painting for Genetic Diagnosis of Diseases.....III-110
New Technique to Detect H1N1 Virus.....III-110
1$75
   B. Market Analytics.....III-111
Table 105: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-111
1$200
   Table 106: Asia-Pacific Historic Review for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1121$200
   Table 107: Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for China and Rest of Asia-Pacific Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-1131$200
   Table 108: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-1141$200
   Table 109: Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1151$200
   Table 110: Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-1161$200
   A. Market Analysis.....III-117
Current and Future Analysis.....III-117
In-Vitro Diagnostics Market on the Growth Curve.....III-117
HPV Testing in China: An Overview.....III-117
1$75
   Government Support Drives Personalized Medicine Market in China.....III-118
Strategic Corporate Development.....III-118
1$75
   B. Market Analytics.....III-119
Table 111: Chinese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-119
1$200
   Table 112: Chinese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1201$200
   Table 113: Chinese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-1211$200
   A. Market Analysis.....III-122
Current and Future Analysis.....III-122
A Focus on the Indian Molecular Diagnostics Market.....III-122
Molecular Diagnostic Market in India to Witness Significant Growth.....III-122
1$75
   Growth Drivers in a Nut Shell.....III-1231$75
   Growing Investments in Pharmacogenomics Research Drives Personalized
  Medicine.....III-124
Indian Scientific Research towards Functional Genomics and Proteomics.....III-124
1$75
   Automation – The Emerging Trend in IVD Industry.....III-1251$75
   Growing Investments in Pharmacogenomics Research Drives Personalized
  Medicine.....III-126
HPV Testing Market: An Overview.....III-126
1$75
   Table 114: HPV in India - Breakdown of Type-Distribution and HPV Prevalence (includes corresponding Graph/Chart).....III-1271$200
   Product Launche/Approval.....III-128
Strategic Corporate Developments.....III-128
1$75
   B. Market Analytics.....III-129
Table 115: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-129
1$200
   Table 116: Rest of Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1301$200
   Table 117: Rest of Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-1311$200
   A. Market Analysis.....III-132
Current and Future Analysis.....III-132
Brazilian IVD Market on the Rise.....III-132
1$75
   B. Market Analytics.....III-133
Table 118: Latin American Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-133
1$200
   Table 119: Latin American Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1341$200
   Table 120: Latin American 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-1351$200
   A. Market Analysis.....III-136
Current and Future Analysis.....III-136
Product Launch.....III-136
1$75
   B. Market Analytics.....III-137
Table 121: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-137
1$200
   Table 122: Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1381$200
   Table 123: Rest of World 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-1391$200
  
Total Companies Profiled: 145 (including Divisions/Subsidiaries - 162)

Region/Country Players

The United States 99 Canada 2 Europe 50 France 5 Germany 11 The United Kingdom 12 Italy 2 Spain 1 Rest of Europe 19 Asia-Pacific (Excluding Japan) 10 Middle East 1
Click here to request a full table of contents and more details on this project.